| Literature DB >> 25979827 |
Stephen G Dann1, Michael Ryskin2, Anthony M Barsotti2, Jonathon Golas2, Celine Shi2, Miriam Miranda2, Christine Hosselet2, Luanna Lemon2, Judy Lucas2, Maha Karnoub3, Fang Wang2, Jeremy S Myers2, Scott J Garza4, Maximillian T Follettie2, Kenneth G Geles2, Anke Klippel3, Robert A Rollins2, Valeria R Fantin4.
Abstract
Lat1 (SLC7A5) is an amino acid transporter often required for tumor cell import of essential amino acids (AA) including Methionine (Met). Met is the obligate precursor of S-adenosylmethionine (SAM), the methyl donor utilized by all methyltransferases including the polycomb repressor complex (PRC2)-specific EZH2. Cell populations sorted for surface Lat1 exhibit activated EZH2, enrichment for Met-cycle intermediates, and aggressive tumor growth in mice. In agreement, EZH2 and Lat1 expression are co-regulated in models of cancer cell differentiation and co-expression is observed at the invasive front of human lung tumors. EZH2 knockdown or small-molecule inhibition leads to de-repression of RXRα resulting in reduced Lat1 expression. Our results describe a Lat1-EZH2 positive feedback loop illustrated by AA depletion or Lat1 knockdown resulting in SAM reduction and concomitant reduction in EZH2 activity. shRNA-mediated knockdown of Lat1 results in tumor growth inhibition and points to Lat1 as a potential therapeutic target.Entities:
Keywords: SLC7A5; S‐adenosylmethionine; cancer metabolism; methionine cycle
Mesh:
Substances:
Year: 2015 PMID: 25979827 PMCID: PMC4516430 DOI: 10.15252/embj.201488166
Source DB: PubMed Journal: EMBO J ISSN: 0261-4189 Impact factor: 11.598